Journal of Clinical and Aesthetic Dermatology

MauiDerm 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/824994

Contents of this Issue

Navigation

Page 26 of 31

S27 JCAD journal of clinical and aesthetic dermatology May 2017 • Volume 10 • Number 5 (Supplement 1) e stimated using the Kaplan-Meier p roduct limit methodology. Results: Significant differences in mean percent change from baseline (improvement) in the PASI were observed between the IXE treatment groups compared with PBO and ETN as early as Week 1 (p<0.001) with mean ( SE) percent improvements of 32.7 (0.76) in IXE Q2W, 33.6 (0.76) in IXE Q4W, 5.31 (1.08) in PBO, and 10.3 (0.76) in ETN. At Week 2, the mean percent improvement was 53.7 (0.86) in IXE Q2W, 53.3 (0.86) in IXE Q4W, 9.25 (1.23) in PBO, and 23.3 (0.86) in ETN. At Week 1, the PASI 50 response rate was 22.8 percent in IXE Q2W and 26.6 percent in IXE Q4W compared with 1.4 percent in PBO (p<0.001) and 3.9 percent in ETN (p<0.001); at Week 2, the PASI 50 response rate was 58.8 percent in IXE Q2W and 57.6 percent in IXE Q4W compared to 4.2 percent in PBO (p<0.001), and 14.6 percent in ETN (p<0.001). Median time (95% CI) to PASI 75 was 31 (30,55) days in the IXE Q4W group, 30 (29,43) days in the IXE Q2W group, and 85 (85,87) days for the ETN group. Conclusion: IXE treatment resulted in clinically meaningful improvements (PASI 50) observed as early as Week 1, which were statistically significantly different compared with ETN and PBO. At least 50 percent of patients had a PASI 75 after approximately four weeks of IXE treatment. Survey Study of Dermatologist and Patient Satisfaction with Halobetasol Propionate Lotion for the Treatment of Plaque Psoriasis Presenters: Neal Bhatia, MD; James Q. Del Rosso, DO Introduction: Halobetasol propionate is a superpotent corticosteroid that is used to treat plaque psoriasis. This survey was d esigned to gather feedback from d ermatologists and patients regarding halobetasol propionate lotion for the treatment of plaque psoriasis. Methods: Dermatologists and patients throughout the United States were selected to enroll in the program. Each dermatologist was given program m aterials for distribution to a maximum of five patients. Selected patients were given one complimentary 60mL bottle of halobetasol propionate lotion and were directed to use the lotion twice a day for two weeks in accordance with the prescribing information. Both patients and dermatologists were encouraged to provide feedback at baseline and at the four-week follow-up visit (2 weeks after the cessation of treatment). Dermatologists self- reported their feedback via a secure website. Patients provided feedback via surveys conducted by a pharmacy case manager. Results: Participating dermatologists responded to 45 patient baseline and end-of-treatment surveys. Patients responded with 82 baseline and end-of- treatment surveys. All results are presented using descriptive statistics (percentages) only. Patients underwent treatment for two weeks, but data were collected at a four-week follow-up appointment. Therefore, results reflect a two-week treatment duration. Dermatologist responses: A total of 84 percent of patients were rated as having plaque psoriasis of at least moderate severity at baseline. By contrast, 43 percent of patients were rated as clear or almost clear following treatment with halobetasol propionate lotion, and 38 percent of patients had mild psoriasis at post-treatment evaluation. At baseline, 27 percent of patients had more than 10 percent of body surface area involvement, but after t reatment, only 11 percent of patients s till had this much area affected. In addition, the percentage of patients with less than three percent of body surface affected doubled from 22 to 44 percent. The great majority (91%) of dermatologists said that halobetasol propionate lotion delivered results that w ere comparable to other superpotent corticosteroid topical formulations. Patient responses: Following treatment, 93 percent of patients reported feeling that their psoriasis improved. Further, 93 percent of patients reported that halobetasol propionate lotion was easy and/or convenient to use, and 95 percent said that it absorbed quickly into the skin. In general, 96 percent of patients reported satisfaction with halobetasol propionate lotion, 93 percent of patients said that they would recommend halobetasol propionate lotion to others with plaque psoriasis, and 88 percent of patients said that they would use halobetasol propionate lotion if their condition were to flare up in the future. Conclusion: Plaque psoriasis can be difficult to treat effectively, and inconsistent adherence to treatment may be an important contributor. Halobetasol propionate lotion was found in this survey study to substantially diminish both the severity of psoriasis and the amount of body surface area involved, as evaluated by dermatologists. The vast majority of patients reported satisfaction with halobetasol propionate lotion. Given this level of dermatologist and patient satisfaction, halobetasol propionate lotion would appear to be an important therapeutic option for the treatment of plaque psoriasis. Ixekizumab in Patients with Moderate-to-severe Psoriasis who Have or Have Not Received Prior

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - MauiDerm 2017